Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 191

Results For "treatment"

4015 News Found

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance
Healthcare | November 26, 2024

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions


Sartorius Stedim Biotech opens center for bioprocess innovation in USA
Biotech | November 22, 2024

Sartorius Stedim Biotech opens center for bioprocess innovation in USA

New research labs and process development services to enable next generation therapeutics


Azenta obtains regulatory approval for clinical long-read whole genome sequencing test
Biotech | November 22, 2024

Azenta obtains regulatory approval for clinical long-read whole genome sequencing test

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory


Emcure and MS Dhoni drive India’s fight against Anemia
Healthcare | November 21, 2024

Emcure and MS Dhoni drive India’s fight against Anemia

Emcure has launched an awareness campaign to help spread the word about male anemia


Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules
Drug Approval | November 20, 2024

Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules

The product will be manufactured at Lupin’s Somerset facility in the US


Lupin launches Bumetanide Injection USP in US
News | November 20, 2024

Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US


Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer
Drug Approval | November 19, 2024

Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years


Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
Clinical Trials | November 19, 2024

Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma

Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex